RxDoctor Payments Data

Mouhamed El Zufari, MD

Family Medicine · The Woodlands, TXNPI 1689669525

Payments from drug & device makers

$7,574in general payments, 2019–2025

Across 431 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • AstraZeneca$1K
  • AbbVie$694
  • Novo Nordisk$679
  • Pfizer$509
  • Lilly USA, LLC$465
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,49699%
  • Education$781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,574 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$61,989
Medicare patients
139
Services billed
1,127

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide93$109,009
OzempicSemaglutide58$81,325
JardianceEmpagliflozin33$42,777
EliquisApixaban36$37,532
JanuviaSitagliptin Phosphate25$34,754
LinzessLinaclotide29$32,950
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$22,678
XareltoRivaroxaban15$16,983
RybelsusSemaglutide12$14,535
FarxigaDapagliflozin Propanediol12$14,186
MyrbetriqMirabegron16$12,239
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$5,342
Atorvastatin Calcium299$3,048
Humalog Kwikpen U-100Insulin Lispro12$2,705
Albuterol Sulfate HfaAlbuterol Sulfate107$2,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$465$109,00993 claims
Novo NordiskOzempic, Rybelsus$679$95,86070 claims
Boehringer IngelheimJardiance$114$42,77733 claims
PfizerEliquis, Paxlovid$509$38,89258 claims
AbbVieLinzess, Synthroid$694$35,34057 claims
MerckJanuvia$73$34,75425 claims
GSKTrelegy Ellipta$1,381$22,67827 claims
Johnson & JohnsonXarelto$51$16,98315 claims
AstraZenecaFarxiga$1,171$14,18612 claims
Astellas Pharma US IncMyrbetriq$164$12,23916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →